Lv4
760 积分 2023-09-27 加入
Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial
1小时前
待确认
Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial
1小时前
待确认
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
2小时前
待确认
Immunotherapy in the First‐Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta‐Analysis
2天前
已完结
Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma
2天前
已完结
Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma
2天前
已完结
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes
2天前
已完结
Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
2天前
已完结
Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)
2天前
已完结
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes
2天前
已完结
皖公网安备34019202002308
